Bertrand Jaber, M.D.
Dr. Bertrand L. Jaber is Vice Chair for Quality Affairs in the Department of Medicine at St. Elizabeth’s Medical Center in Boston, MA, and Professor of Medicine at Tufts University School of Medicine. Dr. Jaber has extensive expertise in dialysis device-related research, translational research in cytokine and leukocyte biology in acute and chronic kidney disease, and hospital-based outcomes research in kidney disease. He has also made contributions to the field of endotoxin binding in experimental settings in an effort to attenuate host inflammatory responses.
Anand Kumar, M.D.
Dr. Anand Kumar is a Professor of Medicine (Critical Care Medicine and Infectious Diseases), Medical Microbiology and Pharmacology/Therapeutics at the University of Manitoba and an attending physician at the Health Sciences Centre and St. Boniface Hospital, Winnipeg, Manitoba, Canada. Dr. Kumar completed fellowships in Critical Care Medicine and Cardiovascular Research at Rush-Presbyterian-St. Luke’s Medical Center in Chicago and in Infectious Diseases at the University of Wisconsin Hospital and Clinics. Dr. Kumar is trained in Internal Medicine, Critical Care Medicine, and Infectious Diseases, with translational research interest in sepsis and life-threatening infections. He has published over 350 original research manuscripts, reviews/chapters, and abstracts. His research manuscripts are among the most cited in the sepsis field.
Steven Opal, M.D.
Dr. Steven Opal is a Professor of Medicine, Infectious Disease Division, Alpert School of Medicine at Brown University and the Chief of Infectious Diseases at Memorial Hospital of Rhode Island (MHRI). Dr. Opal’s research interest focuses on the host-pathogen interaction during the early phase of invasive microbial infection and the pathophysiology of the systemic inflammatory response to infection. Dr. Opal has studied bacterial lipopolysaccharide (LPS or endotoxin) from gram-negative bacteria extensively and has considerable expertise in targeting interventions to limit LPS-mediated diseases. Dr. Opal has served as the principal investigator for numerous worldwide, multi-center trials of adjuvant agents for severe infection and is the lead editor for a major textbook in infectious diseases.
Hermann Goehl is a member of the scientific advisory board of Opsonix. He is an engineer and, prior to his retirement, led the membrane and device technology team at Gambro (Dialysatoren, Germany). He established pilot and large-scale manufacturing processes for both flat sheet and hollow fiber membranes, developing devices with optimal blood compatibility and efficiency for kidney, liver, and lung support systems. Prior to his work at Gambro, he studied Chemical Process Engineering at Technical University Munich and learned the basics of polymer films at Unilever in Germany and Membrane Research at GSRI in New Orleans. He has published over 40 patents and 90 manuscripts in the field of blood purification membranes and devices.
Donald Ingber, M.D., Ph.D.
Donald E. Ingber is a Scientific Founder of Opsonix. He is also the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, as well as the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.
Dr. Ingber is recognized as a leader of the emerging field of biologically inspired engineering. He oversees efforts at the Wyss Institute that strive to identify the mechanisms that living organisms use to self-assemble and auto-regulate, and applies these principles to develop advanced materials and devices for healthcare and the environment. Ingber led the pioneering work that resulted in the development of a blood cleansing device for dialysis-like treatment of sepsis, as well as related companion diagnostic, which form the basis for Opsonix’s pathogen extracting therapy.
Dr. Ingber has also made major contributions to mechanobiology, tissue engineering, tumor angiogenesis, systems biology, nanobiotechnology and translational medicine. He has authored more than 400 publications and 130 patents, and has received numerous honors. He is also a member of the U.S. National Academy of Medicine, National Academy of Inventors, American Institute for Medical and Biological Engineering, and American Academy of Arts & Sciences. Dr. Ingber received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University.
Michael Super, Ph.D.
Michael Super is a Scientific Founder of Opsonix. He is a Senior Staff Scientist and a Lead of the Advanced Technology Team in the Biomimetic Microsystems Platform at the Wyss Institute for Biologically Inspired Engineering at Harvard University. At the Wyss Institute, Dr. Super is Co-Principal Investigator with Dr. Donald Ingber on a DARPA funded project for the dialysis-like treatment of sepsis, which form the basis for Opsonix’s pathogen extracting therapy.
For more than three decades, Dr. Super has conducted preeminent research in pathogen-binding opsonins of the innate immune system. He published the first manuscripts identifying one of these opsonins as the newly described mannan-binding protein (now named mannose binding lectin / MBL), showed that the deficiency of this serum lectin caused clinical disease and frequent unexplained infections and described the molecular basis of the defect. He continued with post-doctoral work on MBL and other C-type lectins at Harvard Medical School and Boston Children’s Hospital.
Dr. Super’s R&D roles in industry included Director of Protein Biochemistry at Lexigen Pharmaceuticals, Director of Immunobiology at EMD Lexigen and Head of Hybridoma Antibody Technologies at EMD Serono. While in industry, he was responsible for preclinical development and Phase 1 through Phase 3 manufacturing of therapeutic monoclonal antibodies and immune-cytokines for cancer treatment including, huKS-IL2, hu14.18-IL2 and EMD 72000, a follower of Erbitux.
Dr. Super has authored 35 publications and over 20 patents. He received his B.Sc. from Manchester Polytechnic Metropolitan University and his M.Sc. and Ph.D. from the University of London.